

## **Increased prevalence of AB blood group and Fya red blood cell antigen in Caucasian SARS-CoV-2 convalescent plasma donors**

Patrick Trépanier<sup>1,#</sup>, Josée Perreault<sup>1</sup>, Gabriel André Leiva-Torres<sup>2</sup>, Nadia Baillargeon<sup>2</sup>, Jessica Constanzo Yanez<sup>2</sup>, Marie-Claire Chevrier<sup>2</sup> and Antoine Lewin<sup>1</sup>

1) Héma-Québec, Medical Affairs and Innovation (Québec City, Québec, Canada),

2) Héma-Québec, Transfusion Medicine, (Québec City and Montréal, Québec, Canada),

### **Corresponding author and author responsible for reprint requests:**

**Patrick Trépanier, Ph.D., M.B.A.**

Héma-Québec, 1070 avenue des Sciences-de-la-Vie, Québec, Qc, Canada G1V 5C3.

Tel.: 418-780-4362, Fax.: 418-780-2091,

E-mail: [patrick.trepanier@hema-quebec.qc.ca](mailto:patrick.trepanier@hema-quebec.qc.ca)

**Short running head:** Covid-19 Convalescent Red Blood Cell typing

The authors have disclosed no conflicts of interest.

This paper has 1567 words excluding references, 2 tables and 19 references.

## Abstract

### Background and Objectives

The SARS-CoV-2 pandemic has put significant additional pressure on healthcare systems throughout the world. The identification of at-risk population beyond age, pre-existing medical conditions and socioeconomic status has been the subject of only a small part of the global COVID-19 research so far. To this day, the extent to which the red blood cell (RBC) antigens expressed by an individual can be associated with SARS-CoV-2 infection or clearance remains unknown.

### Methods

The phenotypes for ABO and RhD and the genotypes for 37 red blood cell (RBC) antigens were determined using high throughput platforms in 90 Caucasian convalescent plasma donors. The antigen frequencies were compared to the expected Caucasian frequencies using Z-tests for two-proportion.

### Results

The AB phenotype and FY\*A allele frequency were both independently and significantly increased (1.5x,  $p=0.018$  and 2.2x,  $p=0.028$ , respectively) in the convalescent cohort (N=90) compared to reference frequencies. The AB phenotype was also significantly overrepresented (3.2x,  $p=0.028$ ) within the FY\*A allele expressing group (N=23). The O group was underrepresented within the cohort proportionally to the AB increase, although non-significantly ( $p=0.110$ ). No other significant RBC antigen expression patterns in the convalescent Caucasian population were identified.

### Conclusion

Our study reveals ABO and Duffy RBC antigen variation among surviving, non-hospitalized Caucasian COVID-19 patients compared to the overall Caucasian population and contributes to the global advancement in understanding COVID-19 potential risk factors.

**Key words:** Covid-19, SARS-CoV-2, Susceptibility, Red Blood Cell Antigens

## **Introduction**

The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused over 4.5 million deaths worldwide as of August 2021 (<https://covid19.who.int/>). Intensive work has been done since the beginning of the pandemic to protect the most at-risk populations. Being male, of older age, obese, of varying ethnic origin, having diabetes, asthma, or many other medical conditions, have all been associated with an increased risk of COVID-19-related complications or death[4, 7, 8, 10, 16]. Genetic factors, such as the expression of angiotensin-converting enzyme (ACE)-related genes, may also play a role in disease severity and could serve as a predictive marker for at-risk populations[19].

The relation between ABO blood group expression and susceptibility for infection by SARS-CoV-2, hospitalization risks and death risks from COVID-19 has been explored by a few groups and recently reviewed [9]. O group individuals were identified as having a decreased risk of infection compared to other ABO groups, although no differences were observed regarding hospitalization and death rates associated with COVID-19[1, 18]. Several hypotheses to explain this observed link between ABO type and risk of infection have been proposed, in regard to the presence of A and B antibody in O individuals[3] and the binding of Receptor-Binding Domain (RBD) to group A antigens[17]. Given the important immunological deregulation and potential

cytokine storm associated with mortality in COVID-19 patients[6] and the interesting report from an Italian laboratory of higher rates of direct antiglobulin test (DAT) reactivity in COVID-19 patients[2], we sought to determine if any trends could be identified in the expression of an extended panel of red blood cell antigens (ABO, RhD and 37 other antigens) within a Caucasian convalescent plasma donor cohort (N=90) compared to reference frequencies. A different prevalence of ABO or other blood groups in Caucasian convalescent individuals, which were infection but not hospitalized, could help design further studies to explain discrepancies observed in the rate of infection in different ethnic groups[10, 13].

## **Material and methods**

### **Samples**

Caucasian convalescent plasmas were randomly chosen from adult participants in the CONCOR-1 clinical trial (#NCT04348656), from the Québec cohort having received an official diagnosis of COVID-19 by the Québec Provincial Health Authority after epidemiologic investigation or confirmed by polymerase chain reaction (PCR) tests. All patients were symptomatic without hospitalization and free of symptoms for at least two weeks before donation and were self-declared Caucasian. The average age of our convalescent plasma donor cohort was  $40.4 \pm 15.0$  years and included 68% males. All donors gave consent to participate in this research project, which was approved by the Héma-Québec Research Ethics Committee. It should be noted that there was no bias for donor recruitment of any specific ABO blood group in the convalescent plasma cohort at the time of random sample selection.

### **Phenotyping and genotyping**

The ABO and RhD phenotype testing was done by serologic detection using the PK7300 from Beckman Coulter as per the manufacturer's protocol. The RBC genotyping was done on the

Luminex xMAP® technology using the ID CORE XT platform (Progenika Biopharma-Grifols, Bizkaia, Spain) as per the manufacturer's protocol, for the following blood group antigens : Rh (C, c, E, e, Cw, hrS, hrB, V, VS), Kell (K, k, Kpa, Kpb, Jsa, Js b), Kidd (Jka, Jkb), Duffy (Fya, Fyb), MNS (M, N, S, s, U, Mia), Diego (Dia, Dib), Dombrock (Doa, Dob, Hy, Joa), Colton (Coa, Cob), Yt (Yta, Ytb) and Lutheran (Lua, Lub). The DNA used for genotyping was extracted using QIAamp Blood Mini kit (Qiagen, Hilden, Germany) from the buffy coats of whole blood samples collected in ethylenediaminetetraacetic acid (EDTA) tubes.

### **Statistical analyses**

Population proportion was assumed to be the true Caucasian prevalence estimates (from Blood Group Antigen FactsBook[11]) while the frequencies of the 90 participants' samples were estimated along with the Clopper-Pearson 95% confidence interval. Z-tests for two-proportion were used to test for statistical significance between populational and observed antigen prevalence. A p value of <0.05 was considered significant.

### **Results**

#### **Red blood cell genotyping**

Allele frequencies for Rh, Kell, MNS, Duffy, Kidd, Diego, Dombrock, Colton, Yt and Lutheran blood groups were determined in each individual, and the resulting predicted phenotypes were compared to the expected Caucasian reference frequencies. The FY\*A/\*A genotype (Fy(a+b-) predicted phenotype) appears to be 1.5x overrepresented (p=0.030) in our convalescent cohort compared to expected frequencies (0.256 vs 0.170, respectively), as presented in Table 1. Incidentally, the FY\*A/\*B (Fy(a+b+) predicted phenotype) individuals appear to be trending towards a decreased frequency of 0.400 compared to the expected 0.490 (Table 1), although

the trend is not significant ( $p=0.087$ ). None of the other antigen group combinations deviated significantly from the expected frequency.

### **ABO and RhD phenotyping**

ABO and RhD phenotypes were determined for each convalescent individual and compared to the expected Caucasian reference frequencies for the entire cohort ( $N=90$ ) and within FY\*A/A individuals ( $N=23$ ). Table 2 shows that the ABO phenotyping analysis for the total cohort allowed for the identification of a significant ( $p=0.0178$ ) 2.2x increase for the AB group compared to reference frequencies (0.089 vs 0.040, respectively). While non-significant ( $p=0.110$ ), the O group trends towards a 0.8x underrepresentation within convalescent individuals compared to expected frequencies (0.356 vs 0.440, respectively). Interestingly, a significant ( $p=0.028$ ) 3.3x AB group overrepresentation was also found within the FY\*A individuals (Table 2, FY\*A/\*A). The same apparent but non-significant decrease in O-group individuals can be observed within the FY\*A/\*A individuals versus the reference frequency (0.304 vs 0.440). No other trending or significant observation was made regarding A and B groups, nor within RhD expression.

### **Discussion**

Our study took a deeper look into the RBC characteristics of a COVID-19 recovered and non-hospitalized cohort enrolled in the CONCOR-1 convalescent plasma study. We used our ABO and RhD automated blood donor testing, as well as our Immunohematology Reference Laboratory RBC genotyping platform to determine the existence of potential trends regarding the frequencies of ABO, Rh and 37 other RBC antigens within the cohort, compared to overall Caucasian prevalence. The AB group was found to be overrepresented, as well as the Fy(a+b-) phenotype, but without a significant variation in Fy(a+b+). These results suggest a possible

involvement of ABO and Duffy red blood cell antigens in SARS-CoV-2 susceptibility and COVID-19 severity, as all these individuals contracted the virus, but cleared it without hospitalization.

Our study has flaws in that it is deficient in providing a more global portrait of RBC characteristics per COVID-19 symptoms gravity, mainly because of our lack of access to different types of COVID-19 subjects, such as hospitalized patients and asymptomatic individuals. Indeed, we lack blood group data from hospitalized, deceased and asymptomatic COVID-19 patients. Blood providers such as Héma-Québec have access to non-hospitalized, convalescent patients, while hospitals have solely access to severely affected and deceased patients. Asymptomatic patients are extremely hard to identify and getting a significant cohort is probably not possible at this time. While the historical ABO frequencies of Quebec's Caucasian blood donors matched that of Factsbook (internal data), such unbiased information about the frequencies of other RBC antigen is not currently available, hence the use of Factsbook Caucasian reference frequencies.

Our study also does not directly address the major RBC antigen expression differences between varying ethnicities. While our convalescent plasma donation program reflected our donors' diversity[15], the low number of non-Caucasian ethnic group individuals was insufficient to conduct statistical analysis, which is unfortunate given the urgency for understanding the disproportionate impact of COVID-19 on minorities[10, 13]. Nonetheless, the identification of a significant overrepresentation of FY\*A/\*A within Caucasian COVID-19 convalescent individuals and the potential implication of the Duffy blood group we have shown could have an impact on future research. The overrepresentation of the Fy(a+b-) predicted phenotype among our COVID-19 convalescent cohort could be explained by the absence of the Fy<sup>b</sup> antigen, since no significant prevalence difference was observed in Fy(a+b+) and Fy(a-b+). In individuals of African descent, the Fy(a-b-) phenotype is caused by a GATA box mutation upstream of the *FY* gene silencing the Fy<sup>b</sup> expression in RBCs[14]. Given that 67% of African Americans (AA) are Duffy

null[5], and that Duffy null patients have an increased mortality rate in Acute Lung Injury[7], some groups have already hypothesized a role for Duffy in COVID-19 AA individuals[5]. We therefore encourage considering Duffy in further research regarding COVID-19 and RBC antigens.

The involvement of ABO blood group in COVID-19 has previously been described[3, 12]. The exact mechanism of action remains elusive, but could be associated to circulating natural anti-A and anti-B antibodies, or a low efficiency furin cleavage in O group individuals[9]. A significant overrepresentation of AB group and the non-significant but trending underrepresentation of the O group within our cohort appear to be in accordance with other groups' suggestion that O individuals could be less susceptible to SARS-CoV-2 infection[1, 18], given that every individual in our study was proved to be infected. The size of our sample does not allow us to conclude if the individuals from the AB group are more susceptible at contracting the virus and better at clearing it without hospitalization, or if this bias is a consequence of the trending underrepresentation of less susceptible to infection O individuals. It would be interesting to consider our observations within larger cohort analyses that include more severely affected patients.

Altogether, we think that our contribution is an important highlight of the potential role for RBC antigen in SARS-CoV-2 infection. More research remains to be done towards a better understanding of potentially at-risk populations in regard to current ongoing healthcare challenges and for future potential and unforeseen pandemics.

### **Acknowledgements**

The authors are grateful to the convalescent plasma donors who participated in this study and the Héma-Québec team involved in convalescent donor recruitment, samples collection, and the



technologists who performed the phenotyping and genotyping workup. The authors are also thankful for healthcare workers' dedication globally.

P.T. designed the research and wrote the manuscript. P.T. and M-C.C. supervised the research. J.P. and J.C.Y. acquired the data. P.T., J.P., N.B., A.L. and J.C.Y. analysed the data. P.T., G.A.L, N.B., M-C.C and J.C.Y. reviewed and edited the manuscript.

**Funding:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## References

1. Barnkob M B, Pottegård A, Støvring H, Haunstrup T M, Homburg K, Larsen R et al. Reduced prevalence of SARS-CoV-2 infection in ABO blood group O. *Blood Advances*. 2020; 4(20): 4990–4993.
2. Berzuini A, Bianco C, Paccapelo C, Bertolini F, Gregato G, Cattaneo A et al. Red cell-bound antibodies and transfusion requirements in hospitalized patients with COVID-19. *Blood*. 2020; 136(6): 766–768.
3. Goel R, Bloch E M, Pirenne F, Al-Riyami A Z, Crowe E, Dau L et al. ABO blood group and COVID-19: a review on behalf of the ISBT COVID-19 working group. *Vox Sanguinis*. 2021: vox.13076.
4. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes/Metabolism Research and Reviews*. 2020. doi:10.1002/dmrr.3319.
5. Hebbel R P, Vercellotti G M. SARS-CoV-2 severity in African Americans – A role for Duffy Null? *Haematologica*. 2020; 105(12): 2892.
6. Hu B, Huang S, Yin L. The cytokine storm and COVID-19. *Journal of Medical Virology*. 2021; 93(1): 250–256.
7. Kangelaris K N, Sapru A, Calfee C S, Liu K D, Pawlikowska L, Witte J S et al. The Association Between a Darc Gene Polymorphism and Clinical Outcomes in African American Patients With Acute Lung Injury. *Chest*. 2012; 141(5): 1160–1169.
8. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F et al. Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission. *Clinical Infectious Diseases*. 2020; 71(15): 896–897.

9. Pendu J L, Breiman A, Rocher J, Dion M, Ruvoën-Clouet N. ABO Blood Types and COVID-19: Spurious, Anecdotal, or Truly Important Relationships? A Reasoned Review of Available Data. *Viruses*. 2021; 13(2): 160.
10. Raisi-Estabragh Z, McCracken C, Bethell M S, Cooper J, Cooper C, Caulfield M J et al. Greater risk of severe COVID-19 in Black, Asian and Minority Ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank. *Journal of Public Health*. 2020; 42(3): 451–460.
11. Reid M E, Lomas-Francis C, Olsson M L. *The Blood Group Antigen FactsBook*. Academic press: 2012.
12. Szymanski J, Mohrmann L, Carter J, Nelson R, Chekuri S, Assa A et al. ABO blood type association with SARS-CoV-2 infection mortality: A single-center population in New York City. *Transfusion*. 2021: trf.16339.
13. Tai D B G, Shah A, Doubeni C A, Sia I G, Wieland M L. The Disproportionate Impact of COVID-19 on Racial and Ethnic Minorities in the United States. *Clinical Infectious Diseases*. 2021; 72(4): 703–706.
14. Tournamille C, Colin Y, Cartron J P, Le Van Kim C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. *Nature Genetics*. 1995; 10(2): 224–228.
15. Trépanier P, Chevrier M, Constanzo Yanez J, Baillargeon N, St-Pierre C, Perreault J. Adapting to supply-and-demand emerging trends for antigen-negative red blood cell units. *Transfusion*. 2021: trf.16285.
16. Williamson E J, Walker A J, Bhaskaran K, Bacon S, Bates C, Morton C E et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020; 584(7821): 430–436.
17. Wu S-C, Arthur C M, Wang J, Verkerke H, Josephson C D, Kalman D et al. The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A. *Blood Advances*. 2021; 5(5): 1305–1309.
18. Wu Y, Feng Z, Li P, Yu Q. Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19. *Clinica Chimica Acta*. 2020; 509: 220–223.
19. Yamamoto N, Ariumi Y, Nishida N, Yamamoto R, Bauer G, Gojobori T et al. SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype. *Gene*. 2020; 758: 144944.

Blood group system	Predicted phenotype	Observed Prevalence	CI 95%	FactsBook Prevalence	p value
Rh	D- C-c+E-e+	0.156	[0.095 – 0.244]	0.151	0.897
	D- C-c+E+e+	0.022	[0.006 – 0.077]	0.009	0.194
	D+ C-c+E+e+	0.100	[0.054 – 0.179]	0.118	0.596
	D+ C+c-E-e+	0.233	[0.158 – 0.331]	0.185	0.242
	D+ C+c+E-e+	0.322	[0.235 – 0.424]	0.349	0.589
	D+ C+c+E+e+	0.167	[0.104 – 0.257]	0.133	0.342
	Cw	0.011	[0.002 – 0.060]	0.020	0.478
	hrS	1.000	[0.959 – 1.000]	0.980	0.174
	hrB	1.000	[0.959 – 1.000]	0.980	0.174
Kell	V	0.000	[0.000 – 0.041]	0.010	0.342
	VS	0.000	[0.000 – 0.041]	0.000	1.000
	K+k-	0.000	[0.000 – 0.041]	0.002	0.675
	K-k+	0.944	[0.876 – 0.976]	0.910	0.259
	K+k+	0.056	[0.024 – 0.124]	0.088	0.286
	Kp(a+b-)	0.000	[0.000 – 0.041]	0.000	1.000
	Kp(a-b+)	0.956	[0.891 – 0.983]	0.977	0.184
	Kp(a+b+)	0.044	[0.017 – 0.109]	0.023	0.184
	Js(a+b-)	0.000	[0.000 – 0.041]	0.000	1.000
MNS	Js(a-b+)	1.000	[0.959 – 1.000]	1.000	1.000
	Js(a+b+)	0.000	[0.000 – 0.041]	0.000	1.000
	M+N+S+s+	0.267	[0.186 – 0.366]	0.240	0.549
	M+N+S-s+	0.144	[0.086 – 0.232]	0.220	0.082
	M-N+S-s+	0.111	[0.061 – 0.193]	0.150	0.298
	M+N-S+s+	0.178	[0.112 – 0.269]	0.140	0.298
	M+N-S-s+	0.122	[0.070 – 0.206]	0.080	0.142
	M-N+S+s+	0.078	[0.038 – 0.152]	0.060	0.472
	M+N-S+s-	0.033	[0.011 – 0.093]	0.060	0.280
Duffy	M+N+S+s-	0.067	[0.031 – 0.138]	0.040	0.190
	U	1.000	[0.959 – 1.000]	0.999	0.764
	Mia	0.000	[0.000 – 0.041]	0.000	1.000
	Fy(a+b-)	0.256	[0.177 – 0.354]	0.170	0.030*
Kidd	Fy(a-b+)	0.344	[0.254 – 0.447]	0.340	0.936
	Fy(a+b+)	0.400	[0.305 – 0.503]	0.490	0.087
	Fy(a-b-)	0.000	[0.000 – 0.041]	Very rare	N/A
	Jk(a+b-)	0.344	[0.254 – 0.447]	0.263	0.082
Diego	Jk(a-b+)	0.222	[0.149 – 0.318]	0.234	0.787
	Jk(a+b+)	0.433	[0.336 – 0.536]	0.503	0.184
	Jk(a-b-)	0.000	[0.000 – 0.041]	Rare	N/A
	Di(a+b-)	0.000	[0.000 – 0.041]	0.000	1.000
Dombrock	Di(a-b+)	1.000	[0.959 – 1.000]	0.999	0.764
	Di(a+b+)	0.000	[0.000 – 0.041]	0.001	0.764
	Do(a+b-)	0.133	[0.078 – 0.219]	0.180	0.246
	Do(a+b+)	0.500	[0.399 – 0.601]	0.490	0.849
	Do(a-b+)	0.367	[0.274 – 0.470]	0.330	0.453
Colton	Hy-	0.000	[0.000 – 0.041]	0.000	1.000
	Jo(a-)	0.000	[0.000 – 0.041]	0.000	1.000
	Co(a+b-)	0.900	[0.824 – 0.946]	0.900	1.000
	Co(a-b+)	0.000	[0.000 – 0.041]	0.005	0.503
Yt	Co(a+b+)	0.100	[0.054 – 0.179]	0.095	0.873
	Co(a-b-)	0.000	[0.000 – 0.041]	0.000	1.000
	Yt(a+b-)	0.889	[0.807 – 0.939]	0.919	0.298
Lutheran	Yt(a+b+)	0.111	[0.061 – 0.193]	0.078	0.242
	Yt(a-b+)	0.000	[0.000 – 0.041]	0.003	0.603
	Lu(a+b-)	0.000	[0.000 – 0.041]	0.002	0.675
	Lu(a-b+)	0.922	[0.848 – 0.962]	0.924	0.944
	Lu(a+b+)	0.078	[0.038 – 0.152]	0.074	0.889
	Lu(a-b-)	0.000	[0.000 – 0.041]	0.000	1.000

\* represents a p value of <0.05

Table 1 – RBC antigen frequencies of the Caucasian convalescent plasma donors compared to reference frequencies

Group	Antigen	Observed Prevalence	CI 95%	FactsBook Prevalence	p value
All donors (N=90)	A	0.456	[0.357 – 0.558]	0.430	0.569
	AB	0.089	[0.046 – 0.166]	0.040	0.018*
	B	0.100	[0.054 – 0.179]	0.090	0.741
	O	0.356	[0.264 – 0.458]	0.440	0.110
	D-	0.178	[0.112 – 0.269]	0.150	0.459
	D+	0.822	[0.731 – 0.888]	0.850	0.459
FY*A/*A individuals (N=23)	A	0.435	[0.256 – 0.632]	0.430	0.960
	AB	0.130	[0.045 – 0.321]	0.040	0.028*
	B	0.130	[0.045 – 0.321]	0.090	0.503
	O	0.304	[0.156 – 0.509]	0.440	0.190

\* represents a p value of <0.05

Table 2 – ABO and D distributions of the Caucasian convalescent plasma donors compared to reference frequencies